Abstract
Lithium was introduced in 1949 as a treatment for mania, for which there is still the strongest evidence of its efficacy. It has consistently yielded better results in the treatment of mania than neuroleptics and carbamazepine and equivalent results to divalproex. Its efficacy in bipolar depression remains inadequately studied. Lithium also provides benefit in prophylaxis. However, the percentage of patients persistently benefited is low, because it has both low efficacy in many symptomatic and illness course presentations of the disorder and low tolerability. Converging evidence from clinical and animal studies indicates that a principal behavioral effect of lithium is reduction of motor activity. Lithium is increasingly used in combined treatment regimens, often thereby allowing lower, better tolerated dosing and complementary benefits from drugs with different profiles of action.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 35-40 |
| Number of pages | 6 |
| Journal | Journal of Clinical Psychiatry |
| Volume | 61 |
| Issue number | SUPPL. 9 |
| State | Published - 2000 |
Fingerprint
ASJC Scopus subject areas
- Psychiatry and Mental health
- Clinical Psychology
Cite this
Efficacy of lithium in mania and maintenance therapy of bipolar disorder. / Bowden, Charles L.
In: Journal of Clinical Psychiatry, Vol. 61, No. SUPPL. 9, 2000, p. 35-40.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy of lithium in mania and maintenance therapy of bipolar disorder
AU - Bowden, Charles L.
PY - 2000
Y1 - 2000
N2 - Lithium was introduced in 1949 as a treatment for mania, for which there is still the strongest evidence of its efficacy. It has consistently yielded better results in the treatment of mania than neuroleptics and carbamazepine and equivalent results to divalproex. Its efficacy in bipolar depression remains inadequately studied. Lithium also provides benefit in prophylaxis. However, the percentage of patients persistently benefited is low, because it has both low efficacy in many symptomatic and illness course presentations of the disorder and low tolerability. Converging evidence from clinical and animal studies indicates that a principal behavioral effect of lithium is reduction of motor activity. Lithium is increasingly used in combined treatment regimens, often thereby allowing lower, better tolerated dosing and complementary benefits from drugs with different profiles of action.
AB - Lithium was introduced in 1949 as a treatment for mania, for which there is still the strongest evidence of its efficacy. It has consistently yielded better results in the treatment of mania than neuroleptics and carbamazepine and equivalent results to divalproex. Its efficacy in bipolar depression remains inadequately studied. Lithium also provides benefit in prophylaxis. However, the percentage of patients persistently benefited is low, because it has both low efficacy in many symptomatic and illness course presentations of the disorder and low tolerability. Converging evidence from clinical and animal studies indicates that a principal behavioral effect of lithium is reduction of motor activity. Lithium is increasingly used in combined treatment regimens, often thereby allowing lower, better tolerated dosing and complementary benefits from drugs with different profiles of action.
UR - http://www.scopus.com/inward/record.url?scp=0033939121&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033939121&partnerID=8YFLogxK
M3 - Article
C2 - 10826659
AN - SCOPUS:0033939121
VL - 61
SP - 35
EP - 40
JO - The Journal of clinical psychiatry
JF - The Journal of clinical psychiatry
SN - 0160-6689
IS - SUPPL. 9
ER -